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The cytokine interleukin-22 (IL-22) is primarily
expressed by T helper 17 (Th17) CD4+ T cells
and is highly upregulated during chronic inflam-
matory diseases. IL-22 receptor expression is
absent on immunecells, but is instead restricted
to the tissues, providing signaling directionality
from the immune system to the tissues. How-
ever, the role of IL-22 in inflammatory responses
has been confounded by data suggesting both
pro- and anti-inflammatory functions. Herein,
we provide evidence that during inflammation,
IL-22 played a protective role in preventing
tissue injury. Hepatocytes from mice deficient
in IL-22 were highly sensitive to the detrimental
immune response associated with hepatitis.
Additionally, IL-22-expressing Th17 cells pro-
vided protection during hepatitis in IL-22-defi-
cient mice. On the other hand, interleukin-17
(IL-17), which is coexpressed with IL-22 and
can induce similar cellular responses, had no
observable role in liver inflammation. Our data
suggest that IL-22 serves as a protective mole-
cule to counteract the destructive nature of the
immune response to limit tissue damage.
INTRODUCTION
Chronic inflammation of the liver inflicted by long-term
infections such as hepatitis B or C viruses or alcohol abuse
often leads to liver disease and cancer later in life. Such
inflammation is associated with T cell activation and the
secretion of numerous proinflammatory cytokines, such
as IFN-g, that damage hepatocytes. In addition to the
proinflammatory factors secreted by T cells, protective
cytokines, such as interleukin-10 (IL-10), allow for more
precise regulation of highly destructive T cell responsesby downregulating the activities of a variety of cells of
the immune system. On the other hand, mechanisms are
needed to regulate tissue responses during inflammation.
T cells secrete interleukin-22 (IL-22), a cytokine that spe-
cifically signals to the tissues and is a good candidate to
mediate protective functions.
IL-22 was discovered as a gene upregulated by CD4+
T cells upon activation, and it shares 22% amino acid
sequence identity with IL-10; it was thus originally named
IL-10-related T cell-derived inducible factor (IL-TIF)
(Dumoutier et al., 2000a, 2000b). However, unlike IL-10,
IL-22 expression appears to be limited to T cells, NK cells,
and NK T cells, as shown by the fact that IL-22mRNA can-
not be detected in resting or activated monocyte-derived
cells or B cells (Wolk et al., 2004). In vivo, within 2 hr of LPS
injection of mice, IL-22 mRNA is upregulated in many
organs harboring lymphocytes, including the spleen, liver,
kidneys, and lung (Dumoutier et al., 2000b). IL-22 has
been found in diseased tissues from patients with different
chronic inflammatory diseases that involve infiltrating
activated T cells, such as rheumatoid arthritis, psoriasis,
and inflammatory bowel disease (Andoh et al., 2005; Ikeu-
chi et al., 2005; Wolk et al., 2004). However, this correla-
tion between IL-22 expression and inflammation has
been further confounded by contrary data indicating
both pro- and anti-inflammatory roles for the cytokine.
Most recently, Zheng et al. showed that IL-22 is important
for mediating IL-23-induced dermal inflammation in a
mouse model of psoriasis, indicating a proinflammatory
role (Zheng et al., 2007).
IL-22 signals through a heterodimer of the receptor
chains IL-22R and IL-10Rb (Kotenko et al., 2001). Because
IL-10Rb is broadly expressed by many different cell types,
IL-22R expression is the limiting component that deter-
mines IL-22 responsiveness of cells. IL-22R is expressed
strongly in the liver, as well as the skin, lungs, pancreas,
and other peripheral tissues (Aggarwal et al., 2001; Wolk
et al., 2004). Resting and activated T cells do not express
IL-22R, and IL-22 stimulation has no observable effects on
T cells (Wolk et al., 2004). Extensive screening of different
cell lines has revealed that only cells which express IL-22RImmunity 27, 647–659, October 2007 ª2007 Elsevier Inc. 647
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receptor that can mediate IL-22 signaling (Wolk et al.,
2005). Thus, it appears that the effects of IL-22 are limited
to peripheral tissues and not on cells of the immune
system.
IL-22 stimulation of IL-22 receptor-expressing cells,
such as hepatocytes, results in activation of Stat3 signal-
ing pathways (Boniface et al., 2005; Lejeune et al., 2002;
Nagalakshmi et al., 2004; Radaeva et al., 2004; Wolk
et al., 2004; Xie et al., 2000). Stat3 signaling leads to the
induction of genes involved in many diverse processes,
including apoptosis, cell-cycle progression, and angio-
genesis, that contribute to both wound healing and cancer
(Dauer et al., 2005). Stat3 is critical to propermouse devel-
opment, and Stat3-deficient mice die early in embryogen-
esis (Takeda et al., 1997). Although liver-specific Stat3-
deficient mice have no abnormalities in liver development,
they do have a reduced ability to recover from liver
damage (Li et al., 2002). IL-22 activation of Stat3 in hepa-
tocytes results in upregulation of expression of acute
phase reactants, such as serum amyloid A (SAA), a1-anti-
chymotrypsin, and haptoglobin, and in vitro IL-22 protects
hepatocytes from serum starvation-induced apoptosis
(Dumoutier et al., 2000b; Radaeva et al., 2004). Thus, IL-
22-mediated activation of Stat3 may play an important
role in hepatocyte survival in vivo. A previous study sug-
gested that IL-22 may play a protective role during acute
liver inflammation (Radaeva et al., 2004). Injection of
recombinant IL-22 prior to treatment with several different
inflammatory molecules reduced the amount of hepato-
cyte damage in the liver. In addition, injection of IL-22
neutralizing antibodies immediately after the inflammatory
molecules exacerbated hepatic injury.
The same subset of CD4+ T cells that express IL-22 also
express interleukin-17 (IL-17) (Liang et al., 2006). IL-17 is
highly expressed by a newly defined subset of helper T
cells, Th17 cells (Weaver et al., 2006). Distinct from Th1
or Th2 cells, differentiation of these cells is dependent
on the presence of both transforming growth factor-
b (TGF-b) and proinflammatory cytokines such as interleu-
kin-6 (IL-6) and tumor necrosis factor-a (TNF-a) (Bettelli
et al., 2006; Mangan et al., 2006; Veldhoen et al., 2006).
Both IL-17 and IL-22 are upregulated in the lesions of
patients with various chronic inflammatory diseases,
such as psoriasis, inflammatory bowel disease, and rheu-
matoid arthritis (Andoh et al., 2005; Chabaud et al., 1998;
Fujino et al., 2003; Liang et al., 2006; Teunissen et al.,
1998; Wolk et al., 2004). Moreover, these cytokines have
been shown to have additive in vitro effects on the induc-
tion of antimicrobial peptides in keratinocytes or cytokines
by colon myofibroblasts (Andoh et al., 2005; Liang et al.,
2006). These data suggest that IL-22 and IL-17 may serve
similar roles in vivo during inflammation.
In this study, we show that IL-22 is important in vivo for
limiting hepatocyte damage during acute liver inflam-
mation. Under specific-pathogen-free conditions, IL-22-
deficient mice had normal immune systems and liver
pathology. However, these mice were extremely suscep-
tible to liver damage during conA-mediated hepatitis, and
648 Immunity 27, 647–659, October 2007 ª2007 Elsevier Inc.therefore, IL-22 protected hepatocytes from the destruc-
tive effects of activated T cells. We show that IL-22-
expressing Th17 cells, but not IL-22-deficient Th17 cells,
provided protection to hepatocytes during hepatitis.
However, although IL-17, like IL-22, is induced during
conA-mediated hepatitis, our data suggest that IL-17 did
not play an observable role in disease pathogenesis in
this model. Therefore, although IL-22 and IL-17 are coex-
pressed by inflammatory T cells, these cytokines can have




To investigate the in vivo role of IL-22 during liver inflam-
mation, we generated IL-22-deficient mice (Figure S1 in
the Supplemental Data available online). IL-22-deficient
mice were viable and fertile, and pups were born at the
expected Mendelian ratio. Upon histological examination
of different organs, including the liver, spleen, kidney,
skin, pancreas, and thymus, we observed no abnormali-
ties at 8 weeks of age (Figure S2). We also compared
the total numbers and activation status of different
immune cell subsets (CD4+ T cells, CD8+ T cells, NK T
cells, and NK cells) in the spleens and livers of IL-22-defi-
cient and wild-type littermates and found no differences
(data not shown). After T cell receptor stimulation, CD4+
T cells from wild-type but not IL-22-deficient mice had
detectable expression of IL-22 mRNA or secreted protein
(Figure S3).
Because IL-22 is highly expressed by CD4+ T cells, as
well as NK cells and NK T cells, we wanted to determine
whether IL-22 deficiency resulted in any in vivo defects
in innate or adaptive immunity. To analyze this, we used
the infection model of Listeria monocytogenes in which
both innate and adaptive immune responses have been
well characterized. This facultative intracellular Gram-
positive bacterium induces both NK cell and CD4+ T cell
responses. NK cells play a role in the clearance of bacteria
by secreting IFN-g that activates macrophages. L. mono-
cytogenes infection also generates strong L. monocyto-
genes-specific CD4+ T cell responses. To examine innate
immunity, we therefore infected IL-22-deficient and
wild-type littermate control mice with 53 104 CFU of wild-
type L. monocytogenes. Three days after infection, the
peak of the innate immune response, we observed no
difference in bacterial loads in the spleens and livers
between IL-22-deficient and wild-type mice (Figure S4).
To examine the antigen-specific T cell response, we
infected wild-type and IL-22-deficient mice with 1 3 104
CFU of recombinant strain of L. monocytogenes that
expresses ovalbumin (rLM-ova). At 7 days after infection,
both IL-22-deficient and wild-type mice had an increased
percentage of activated cells (CD44high, CD62Llow) in their
spleens compared to uninfected mice (Figure S5). To
quantitate the antigen-specific response, lymphocytes
from the spleens and livers of infected mice were
stimulated in vitro with the MHC class II-restricted
Immunity
IL-22 and IL-17 Have Distinct Inflammatory RolesFigure 1. Hepatocytes Are Highly Responsive to IL-22
(A) IL-22R, IL-10Ra, IL-10Rb mRNA expression in different cell subsets by real-time RT-PCR. Bars represent the ratio of gene to hypoxanthine-
guanine phosphoribosyltransferase (HPRT) expression as determined by the relative quantification method (DDCT). ND = not detected.
(B and C) FL38B cells (B) or bone marrow-derivedmacrophages (C) were left untreated (Ø) or stimulated for 20min with 50 ng/ml recombinant murine
IL-10 or IL-22. Phosphorylation or total Stat3 and b-actin in the cell lysates were determined by immunoblotting with the respective antibodies.
(D) FL38B cells were either serum starved for 5 hr (FBS) or remained in media with serum (+FBS) and then stimulated with 50 ng/ml recombinant IL-
22 for 0, 10, or 30 min. Phosphorylation or total Akt and b-actin in the cell lysates was determined by immunoblotting with the respective antibodies.
Experiment was performed four times with similar results.L. monocytogenes-derived epitope, LLO190-201, or the
MHC class I-restricted epitope, OVA257-261. Both IL-22
wild-type and deficient mice generated similar percent-
ages of LLO190-201-specific cells in their spleens and
livers (Figure S5), as well as OVA257-261-specific cells
(Figure S6). Thus, IL-22-deficient mice appear to have
normal innate and adaptive immune responses against
the pathogen L. monocytogenes.
IL-22 Stimulation ofMurine Hepatocytes Activates
Stat3 and Akt Signaling Pathways
IL-22 is expressed by effector CD4+ T cells, NK cells, and
NK T cells, the populations of which are all enriched in the
mouse liver. However, these cells do not express IL-22R.
As reported in the literature, IL-22RmRNA expression was
not detectable in immune cell subsets, including CD4+
T cells, macrophages, and B cells, but these cells did
express IL-10Ra and IL-10Rb mRNA (Figure 1A). On the
other hand, as previously shown by other studies, hepato-
cytes expressed high amounts of IL-22R and IL-10Rb
mRNA, whereas IL-10Ra mRNA expression was unde-
tectable (Figure 1A). Stimulation of the murine hepatocyte
cell line FL38B with recombinant murine IL-22, but not IL-
10, resulted in activation of Stat3 and Akt as observed by
increased phosphorylation of these two signaling mole-
cules (Figures 1B and 1D). As expected, recombinantmurine IL-10, but not IL-22, induced Stat3 activation in
bone marrow-derived macrophages (Figure 1C). These
data indicate that murine hepatocytes are a target of
IL-22 but not IL-10.
IL-22-Deficient Mice Are Highly Susceptible
to ConA-Mediated Acute Liver Inflammation
Hepatitis is a complex of diseases of the liver in which
activated T cells are frequently responsible for mediating
hepatocyte damage. An experimental model of this
disease is conA-mediated hepatitis, in which the lectin
concanavalin A (conA) is injected intravenously into mice
and is selectively retained by the liver. This stimulates
the CD4+ T cells and NK T cells in a polyclonal manner,
inducing a rapid T cell-mediated liver disease because
of upregulation of both IFN-g and FasL (Takeda et al.,
2000; Tiegs et al., 1992; Toyabe et al., 1997). Injection of
mice with conA also leads to rapid induction of IL-22
mRNA in liver lymphocytes (Figure 2). To examine the
role of IL-22 in acute liver inflammation, we injected IL-
22-deficient, IL-22 heterozygous, and IL-22 wild-type
control mice with conA. After injection with 10 mg/gmouse
conA, some IL-22-deficient mice (32%) and IL-22 hetero-
zygous mice (25%) succumbed to mortality before 18 hr
post-injection; however, no wild-type mice ever exhibited
any outward signs of morbidity. At greater doses of conAImmunity 27, 647–659, October 2007 ª2007 Elsevier Inc. 649
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gous mice died by 18 hr after injection, whereas IL-22
wild-type mice survived.
To examine whether this mortality was associated with
increased liver damage, we examined amounts of alanine
aminotransferase (ALT) and aspartate aminotransferase
(AST) in the serum, as well as liver histology. After conA
treatment, compared to wild-type or heterozygous mice,
IL-22-deficient mice had higher amounts of ALT and
AST in their sera, indicative of liver damage (Figure 3D;
Figure S7). No differences were observed in the ALT
amounts of PBS-only mice, indicating that the IL-22-defi-
cient mice do not have liver disease under nonexperi-
mental conditions (Figure 3C). Upon examination of liver
pathology, IL-22-deficient mice injected with conA had
more extensive lesions, as well as a greater number of
lesions in their livers (Figure 3A). Lesions were most com-
monly found on the perimeter of the lobes, especially the
left and median lobes. IL-22 heterozygous mice had an in-
termediate phenotype between IL-22-deficient and IL-22
wild-type mice and thus were excluded from the remain-
der of our studies.
IL-22-deficient mice have more extensive liver damage
in response to conA-mediated hepatitis than wild-type
mice. Because IL-22 is expressed by T cells, along with
the potent cytokines that mediate disease such as IFN-
g, we examined whether IL-22-deficient and wild-type
Figure 2. IL-22 mRNA Is Upregulated in the Liver during
ConA-Mediated Hepatitis
C57BL/6 mice were intravenously injected with the indicated dose of
conA, and 2 hr later mRNA was harvested from the livers. mRNA
was reverse transcribed, and IL-22 and IFN-g cDNA were quantitated
by real-time PCR. Bars represent the mean ± SD expression of the
cytokine gene to HPRT with the DDCT method. Experiment was
performed twice with similar results. ND = not detected.
650 Immunity 27, 647–659, October 2007 ª2007 Elsevier Inc.control mice have equal immune responses to conA-
mediated hepatitis. IL-22-deficient and wild-type control
mice had equal induction in the liver of IFN-g, TNF-a, IL-
4, IL-15, IL-6, and IL-10 mRNA 6 hr after conA administra-
tion, aswell as IFN-g and TNF-a amounts in their sera (Fig-
ures 4A and 4B). In addition, CD4+ T cells from the spleens
and livers of wild-type and IL-22-deficient mice both
rapidly upregulated surface expression of the early ac-
tivation marker CD69 (Figure 4C). Thus, the increased
liver damage observed in IL-22-deficient mice after conA
administration is not due to an increased immune
response in these mice, but instead suggested that it
may be due to increased susceptibility of hepatocytes to
the destructive immune response.
Hepatocyte Damage in IL-22-Deficient Mice
Is Dependent on Inflammation and Not
Hepatocyte Apoptosis
An alternate hypothesis to explain the increased hepatic
lesions in IL-22-deficient mice during inflammation is
that these hepatocytes have a greater intrinsic suscep-
tibility to apoptosis. To examine whether hepatocytes
from IL-22-deficient mice were more susceptible to
apoptosis independent of inflammation and hence in the
absence of IL-22, we compared hepatocyte responses
to an activating Fas Ab (clone Jo2). Injection of mice
with this Ab leads to hepatocyte apoptosis because these
cells are particularly sensitive to Fas-FasL-mediated kill-
ing (Ogasawara et al., 1993). Injection of mice with Fas
Ab did not induce IFN-g mRNA in the liver, unlike conA
injection (Figure 5C). However, Ab injection did induce
equal amounts of TNF-a in the livers of IL-22 wild-type
and deficient mice (Figure 5D). As expected, IL-22
mRNA was not detected in the spleen or liver after anti-
Fas treatment (data not shown). IL-22-deficient and
wild-type control mice both had comparable sera ALT
amounts 6 hr after injection (Figure 5B). In addition, we
observed no difference in hepatocyte injury between IL-
22-deficient and control mice (Figure 5A). Thus, in the
absence of IFN-g-induced inflammation, wild-type and
IL-22-deficient mice had similar liver damage, indicating
that hepatocytes of IL-22-deficient mice are not more
intrinsically susceptible to apoptosis.
IL-6 Is Not Required for IL-22 Induction
during Hepatitis
The susceptibility of IL-22-deficient mice to conA-medi-
ated hepatitis is reminiscent of the phenotype observed
in IL-6-deficient mice. IL-6-deficient mice also have
greater hepatocyte damage after conA-mediated hepati-
tis than wild-type mice, which correlates with a reduced
degree of Stat3 activation in hepatocytes of IL-6-deficient
mice (Hong et al., 2002; Tagawa et al., 2000). Furthermore,
IL-6 is an important cytokine in the in vitro differentiation
of IL-22-expressing Th17 cells (Liang et al., 2006; Zheng
et al., 2007). In the absence of TGF-b or when there are
only very low amounts of TGF-b, IL-6 preferentially leads
to differentiation of Th17 cells expressing substantially
greater amounts of IL-22 than IL-17, whereas IL-17
Immunity
IL-22 and IL-17 Have Distinct Inflammatory RolesFigure 3. IL-22-Deficient Mice Are Highly Susceptible to ConA-Induced Acute Liver Inflammation
IL-22 wild-type (Il22+/+), heterozygous (Il22+/), and deficient (Il22/) mice were intravenously injected with 10 mg/g conA or injected with PBS.
(A) 18 hr or 5 days after injection, mice were euthanized, and livers were harvested, fixed, sectioned, and stained with H&E. Shown are representative
sections from one of three mice per group.
(B) Higher magnification of a lesion from an Il22/ mouse, 18 hr after conA.
(C and D) ALT amounts in the sera of mice injected 18 hr previously with (C) PBS or (D) conA. Bars represent mean ± SD of three mice per group.
Experiment was performed three times with similar results.expression is greater than that of IL-22 in the presence of
higher amounts of TGF-b (Zheng et al., 2007). Therefore,
to investigate whether IL-6 is required in vivo for the
induction of IL-22 during conA-mediated hepatitis, we
compared IL-22 expression between wild-type and IL-6-
deficient mice. By 2 hr after conA injection, IL-6 mRNA
was induced in the livers of wild-type mice and decreased
by 4 hr (Figure S8). As expected, no IL-6 mRNA was
detected in IL-6-deficient mice. At both 2 and 4 hr after
conA injection, there was no significant difference in IL-
22 mRNA induction between IL-6-deficient and wild-
type control mice. Thus, IL-6 is dispensable in vivo for
induction of IL-22 in the liver during hepatitis.
IL-17 Has No Observable Function
in ConA-Mediated Hepatitis
Both IL-22 and IL-17 are expressed by inflammatory T
cells and both cytokines are upregulated in the lesions
of chronic inflammatory diseases such as psoriasis,inflammatory bowel disease, and rheumatoid arthritis
(Andoh et al., 2005; Chabaud et al., 1998; Fujino et al.,
2003; Liang et al., 2006; Teunissen et al., 1998; Wolk
et al., 2004). Recent studies have observed that the effects
of IL-22 on cells are similar to the effects of IL-17 and
showed that stimulation of cells with both cytokines has
an additive effect. Both cytokines induce expression of
antimicrobial peptides in keratinocytes, as well as cyto-
kine secretion by colon myofibroblasts (Andoh et al.,
2005; Liang et al., 2006). As for IL-22, stimulation of
some cell types with IL-17 activates Akt and Stat3 (Hwang
et al., 2004; Subramaniam et al., 1999). As we had
observed for IL-22, IL-17mRNAwas induced in the spleen
and liver upon conA injection (Figure 6A) and IL-17A
protein was detected in the sera (Figure 6B). Thus, we
hypothesized that IL-17 may also play a role during acute
liver inflammation.
IL-17-deficientmice, however, exhibited nodifference in
liver injury compared to wild-type mice 18 hr after conAImmunity 27, 647–659, October 2007 ª2007 Elsevier Inc. 651
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IL-22 and IL-17 Have Distinct Inflammatory RolesFigure 4. IL-22-Deficient and Wild-Type Mice Have Equal Immune Responses during ConA-Mediated Hepatitis
Il22 wild-type (Il22+/+) and deficient (Il22/) mice were intravenously injected with 10 mg/g conA or left untreated, and 6 hr later the resulting immune
response was analyzed.
(A) Cytokine mRNA expression in the liver was semiquantitated by real-time RT-PCR by the DDCT method. Bars represent mean ± SD of four mice.
(B) IFN-g and TNF-a amounts in the sera of mice were determined by ELISA. Bars represent mean ± SD of 6–8 mice per group.
(C) Activation of CD4+ T cells from the livers and spleens was analyzed by surface expression of CD69 by FACS. Number represents the percentage of
CD4+ cells that are CD69high. Shown are representative FACS plots of one mouse of three mice per group.injection. Both groups had similarly elevatedALTamounts,
as well as limited necrotic lesions in their livers (Figures 6C
and 6D). To determine whether IL-17 could play a role in
hepatitis in the absence of IL-22, we generated IL-22 and
IL-17 double-deficient mice. ConA injection of these
mice led to extensive hepatocyte injury (Figures 6C and
6D). However, this damage was not substantially different
from that observed in IL-22-deficient mice. These data
suggest that IL-17 does not protect from liver damage dur-
ing hepatitis, nor does it appear to increase the damage,
and thus, IL-17 appears to play no role in hepatocyte dam-
age during conA-mediated hepatitis.652 Immunity 27, 647–659, October 2007 ª2007 Elsevier Inc.Because we did not observe differences in liver damage
between wild-type and IL-17-deficient mice, or between
IL-22-deficient mice and IL-22 and IL-17 double-deficient
mice, we investigated the in vitro hepatocyte response to
IL-17. To determine whether hepatocytes respond to IL-
17, we stimulated FL38B cells with IL-22 or IL-17 and
examined whether there was subsequent Stat3 and/or
Akt activation. As previously observed, IL-22 induced
both Stat3 and Akt phosphorylation (Figure 6E). However,
hepatocytes did not respond in this way to IL-17 stimula-
tion. Therefore, unlike the protective role of IL-22 on hepa-
tocytes during liver inflammation, IL-17 expressed in the
Immunity
IL-22 and IL-17 Have Distinct Inflammatory RolesFigure 5. Hepatocyte Damage in IL-22-Deficient Mice Is Dependent on Inflammation and Not Inherent Susceptibility of
Hepatocytes to Apoptosis
IL-22-deficient (Il22/) or control wild-type (Il22+/+) mice were injected intraperitoneally with 1 mg/g mouse of anti-Fas (clone Jo-2) or PBS and were
euthanized 6 hr later.
(A) Representative liver sections stained with H&E.
(B) ALT in the sera of Jo2-injected mice, mean ± SD of four mice per group.
(C and D) Induction of (C) IFN-g and (D) TNF-amRNA in the livers of Jo2-injected (Jo2) or conA-injected (ConA) mice compared to untreated mice (Ø)
as quantitated by real-time RT-PCR by the DDCT method. Experiment was performed three times with similar results.liver during hepatitis does not appear to play a role in
hepatocyte responses to inflammation. Although these
cytokines are coexpressed by activated T cells and have
similar effects on keratinocytes and colon myofibroblasts,
IL-22 and IL-17 have distinct roles during acute liver
inflammation.
IL-22-Expressing Th17 Cells Provide Protection
to Hepatocytes during Hepatitis
To determine whether IL-22-expressing CD4+ T cells are
able to provide protection to hepatocytes during hepatitis,
we employed an adoptive transfer model. Naive IL-22
wild-type or deficient CD4+ T cells were differentiated
into effector cells under Th17-polarizing conditions for
5 days. Compared to restimulated cells cultured under
neutral (Th0) conditions, restimulation of these cells re-
sulted in 1000-fold induction of IL-22 and more than
10,000-fold induction of IL-17, as well as low amounts of
IFN-g (Figure 7A). IL-22 wild-type and deficient cells
expressed equal amounts of IL-17 and IFN-g. 5 3 106
nonrestimulated Th17 cells, either IL-22 wild-type or defi-
cient, were transferred into IL-22-deficient host mice and
then mice were injected with conA to induce hepatitis.
IL-22-deficient mice that received wild-type cells had
reduced serum levels of ALT and AST at 6 and 18 hr after
conA (Figures 7B and 7C). These data indicate that IL-22-
expressing Th17 cells are able to provide protection to
hepatocytes during conA-mediated hepatitis.
DISCUSSION
IL-22 has been most commonly described as a proinflam-
matory cytokine because of its expression in lesions ofpatients with chronic inflammatory diseases and its induc-
tion of proinflammatory cytokines such as IL-6, IL-8, and
TNF-a (Andoh et al., 2005; Brand et al., 2006). IL-22 has
recently been shown to be an important mediator in vivo
for dermal inflammation (Zheng et al., 2007). However,
other data suggest that IL-22 has a less direct inflamma-
tory role and instead induces expression of genes associ-
ated with antimicrobial defense and cellular differentiation
(Boniface et al., 2005; Wolk et al., 2004, 2006). Our data
indicate that in vivo IL-22 also functions to protect hepato-
cytes from the destructive effects of immune cells in the
inflamed liver. In an acute hepatitis model, mice deficient
in IL-22 exhibited extensive liver damage compared to
wild-type mice.
IL-22 stimulation of hepatocytes leads to activation of
both Stat3 and Akt signaling pathways. Triggering both
of these well-described pathways leads to activation of
cell survival genes that are involved in promoting cell-
cycle progression and cellular transformation and in pre-
venting apoptosis, as well as specifically involved in liver
regeneration (Haga et al., 2005; Li et al., 2002). IL-22 pro-
tects hepatocytes from in vitro serum starvation in a Stat3-
dependent manner, potentially through induction of antia-
poptotic proteins such as Bcl-2 and Bcl-xL (Radaeva
et al., 2004). IL-22 also has mitogenic activities and in-
duces expression of such proteins as c-myc and cyclin
D1 (Radaeva et al., 2004); however, this activity probably
plays little role in our rapid phenotype during conA-medi-
ated hepatitis. The role of Akt in hepatocytes is less well
elucidated but has been shown to be compensatory for
Stat3 in its absence (Haga et al., 2005). We speculate
that these signaling pathwaysmay synergize to induce ex-
pression of antiapoptotic factors. During conA-mediatedImmunity 27, 647–659, October 2007 ª2007 Elsevier Inc. 653
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IL-22 and IL-17 Have Distinct Inflammatory RolesFigure 6. IL-22 and IL-17 Have Nonhomologous Roles in ConA-Mediated Hepatitis
(A) C57BL/6 mice were injected with 10 mg/g conA or PBS alone. 2 hr later, IL-17 mRNA induction in the spleen compared to PBS mice was quan-
titated by real-time RT-PCR by the DDCT method. Bars indicate mean ± SD.
(B) IL-17A protein amounts in the sera of C57BL/6 mice 6 hr after conA injection. Bar indicates mean ± SD. ND = not detected.
(C) Wild-type (Il22+/+ Il17a+/+), IL-22-deficient (Il22/ Il17a+/+), IL-17-deficient (Il22+/+ Il17a/), or IL-22 IL-17 double-deficient (Il22/ Il17a/) mice
were intranvenously injected with 10 mg/g conA, and 18 hr later liver injury was examined. ALT (mean ± SD) in the sera of conA-injected mice.
(D) H&E liver sections from the indicated mice from (C). Shown are representative sections from one mouse of three per group.
(E) FL38B cells were stimulated for 20 min with 50 ng/ml of recombinant murine IL-22 or IL-17 or left unstimulated (Ø). Phosphorylation of Stat3 and
Akt in the cell lysates was examined by immunoblotting with phospho-specific Abs as described in the Experimental Procedures.hepatitis, we found that mRNA of the antiapoptotic Bcl-2
was induced approximately 1000-fold in the liver (data
not shown). However, in IL-22-deficient mice, this induc-
tion was attenuated and only about 200-fold. Thus, IL-22
itself may not induce proinflammatory responses, but
instead is an important component of the inflammatory
response to limit tissue damage.
IL-22 has homology to IL-10 and its heterodimeric re-
ceptor shares use of the IL-10Rb chain. Because of the
mutual exclusive expression of IL-10Ra and IL-22R, no
known cell type is responsive to both cytokines. IL-10 is
a master regulator of the immune response that mediates
downregulation of proinflammatory cytokine expression
in macrophages, T cells, and other cells of the immune
system (Moore et al., 2001). IL-10 is responsible for damp-
ening the immune response that indirectly protects the
host from potentially detrimental immunopathologic
effects. On the other hand, IL-22 has no observable654 Immunity 27, 647–659, October 2007 ª2007 Elsevier Inc.effects on cells of the immune response but instead acts
primarily on the tissues (Wolk et al., 2004). In a sense, dur-
ing inflammation, IL-22 directly protects the host’s tissues
from the destructive immune response. Thus, both IL-10
and IL-22 may have evolved to safeguard the host from
a potentially overwhelming immune response by acting
on immune and tissue cells, respectively.
IL-22 may be structurally homologous to IL-10, but
IL-22 has recently been shown to be coexpressed with
a structurally unrelated cytokine, IL-17. These two cyto-
kines are expressed by the newly identified Th17 CD4+ T
cell subset (Chung et al., 2006; Liang et al., 2006). IL-6
acts as a sufficient cytokine for the in vitro differentiation
of IL-22-expressing Th17 cells contrary to the requirement
of additional TGF-b for the optimal expression of IL-17
(Zheng et al., 2007). However, our data provide evidence
that IL-6 is not required for the in vivo generation of
IL-22-expressing cells because IL-6-deficient mice
Immunity
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have shown herein that IL-22 expression by these cells
can mediate hepatocyte protection during hepatitis.
As for IL-22, IL-17 has been described to be a proinflam-
matory cytokine; however, like IL-22, much remains to be
Figure 7. Th17 Differentiated IL-22-Expressing Cells Protect
Hepatocytes during Hepatitis
IL-22 wild-type (Il22+/+) or deficient (Il22/) naive (CD44low, CD62Llow,
CD25) CD4+ T cells were differentiated in vitro with plate-bound
a-CD3 plus a-CD28 for 5 days under Th0 or Th17 conditions.
(A) Cells were stimulated with PMA and ionomycin or remained unsti-
mulated. 5 hr after stimulation, mRNA was harvested and reverse tran-
scribed, and cDNA was quantitated by real-time RT-PCR. Induction
over unstimulated cells was calculated by the DDCT method. ND =
not detected.
(B) 53 106 Il22+/+ or Il22/ Th17 cells were injected into Il22/mice,
and then 6–12 hr later, mice were injected with 10 mg/g conA. 6 and
18 hr after conA injection, ALT and AST in the sera was quantitated,
mean ± SD for 6 mice per group. A similar experiment yielded similar
results.elucidated about the in vivo role of this cytokine in inflam-
mation. IL-17 induces expression of IL-6 and IL-8, is
important for neutrophil infiltration, and is critical for full
disease pathogenesis of the highly inflammatory experi-
mental autoimmune encephalomyelitis model (Fossiez
et al., 1996; Hofstetter et al., 2005; Komiyama et al.,
2006; Stark et al., 2005; Yao et al., 1995). Although IL-22
and IL-17 have been shown to have similar effects on
keratinocytes and colon myofibroblasts, we have shown
that they do not have parallel effects in the liver. Unlike
IL-22-deficient mice, IL-17-deficient mice had no differ-
ence in their response to conA-mediated hepatitis,
although conA did induce IL-17 expression. This may be
due to redundancy in the effects of IL-17 with IL-17F,
which is also induced in the liver during conA-mediated
hepatitis (data not shown). However, hepatocytes do not
appear to respond to IL-17, although IL-17RA and IL-
17RC mRNA can be detected in the liver and hepatocyte
cell lines (data not shown). IL-22R and IL-17RA expression
are not overlapping. IL-22R is expressed in the tissues and
absent from cells of hemapoetic origin. On the other hand,
IL-17RA is expressed in both the tissues and by cells of the
immune system, such as T cells and macrophages (Yao
et al., 1995). Therefore, Th17 cells secreting both IL-22
and IL-17 may target different cell subsets during an
immune response. In this way, IL-22 may act on the
tissues and upregulate expression of prosurvival genes,
whereas IL-17 may serve a role in directing the immune
response.
IL-22 and IFN-g appear to have little direct effects on
each other. The genes encoding these cytokines are situ-
ated in tandem on mouse chromosome 10 (Dumoutier
et al., 2000a); however, it does not appear that the two
cytokines are coexpressed (Liang et al., 2006). Moreover,
under several different stimulatory conditions, our experi-
ments show that IL-22-deficient mice expressed as much
IFN-g as wild-type mice and IFN-g-deficient CD4+ T cells
expressed equivalent amounts of IL-22 mRNA as wild-
type cells (data not shown). Hepatocytes express both
IL-22R and IFN-gR; however, they potentially respond
differently to these cytokines because IFN-g preferentially
activates Stat1, whereas IL-22 mainly activates Stat3. In
keratinocytes, IFN-g or IL-22 stimulation results in very dif-
ferent expression profiles (Wolk et al., 2006). IFN-g stimu-
lation results in upregulation of MHC-related molecules,
cytokines, chemokines, and their receptors, whereas IL-
22 stimulation leads to upregulation of expression of
genes encoding antimicrobial defensins and proteins
that increase cellular motility. Our data suggest that during
conA-mediated hepatitis when both cytokines are in-
duced, IL-22 protects hepatocytes from the destructive
effects of IFN-g.
IL-22 may have promise as a potential therapeutic for
chronic inflammatory diseases. Treatment with recombi-
nant cytokine or gene therapy delivery of IL-22 may allevi-
ate tissue destruction during inflammatory responses.
Experimental delivery of IL-22 has been efficacious in
treating autoimmune disorders such as experimental
autoimmune myocarditis in rats (Chang et al., 2006; PanImmunity 27, 647–659, October 2007 ª2007 Elsevier Inc. 655
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inflammatory treatments such as TNF-a inhibitors can
lead to unwanted dampening of the immune response,
weakening its ability to respond to infection. On the other
hand, IL-22 is an ideal therapeutic candidate because it
will specifically affect tissue responses and not have direct
effects on the immune response.
Chronic inflammation is also linked to the development
of cancer (Karin et al., 2006). Sustained tissue damage
and oxidative DNA damage from toxic immune infiltrates
and damage-induced proliferation can act as tumor pro-
moters. Epidemiological studies show that patients with
many different chronic inflammatory diseases are at
increased risk for developing cancer in those inflamed
organs (Lu et al., 2006). Chronic hepatitis B virus (HBV)
or hepatitis C virus (HCV) infection, as well as long-term
alcohol abuse, lead to hepatocyte damage that ultimately
results in liver cirrhosis, and most hepatocellular carcino-
mas (HCCs) form in cirrhotic livers. In addition, HBV or
HCV chronic carriers have a 50%–60% lifetime risk of
developing HCCs (Blum, 2005). HCC is one of the most
common cancers world-wide and is also responsible for
a high number of cancer-related deaths. Because most
HCCs occur in liver-disease patients, it will be very bene-
ficial to develop preventative therapies aimed at interfer-
ing with HCC development in these predisposed patients.
During acute liver inflammation, IL-22 protects hepato-
cytes from injury, possibly through Stat3-mediated upre-
gulation of prosurvival and proliferative responses. IL-22
may also contribute to limiting damage during chronic in-
flammation, and recombinant IL-22 therapy may prevent
development of HCCs. However, IL-22 may have oppos-
ing short-term and long-term effects in the liver. Expres-
sion of IL-22 during chronic inflammation may allow for
survival of damaged hepatocytes that are precursors for
HCCs and therefore may promote cancer. Future studies
will examine the role of IL-22 in chronic inflammation and
the development and treatment of liver cancer. IL-22 may
prove to be an important target for developing new drugs
and treatments to combat liver diseases.
EXPERIMENTAL PROCEDURES
Construction of IL-22-Deficient Mice and a Description
of Other Mice Used in This Study
Il22/ mice were generated by the VelociGene approach as de-
scribed (Valenzuela et al., 2003). In brief, embryonic stem cells were
targeted with the construct indicated in Figure S1. A pZEN6 cassette
was constructed, in which a reporter lacZ gene was placed in tandem
with a neomycin resistance gene flanked by loxP sites and driven by
a promoter that allowed for positive selection in both bacterial and
mammalian cells. The pZEN6 cassette was ligated to double-stranded
oligonucleotides and used for the generation of a bacterial artificial
chromosome-based targeting vector. To generate chimeric mice defi-
cient in IL-22, correctly targeted embryonic stem cells derived from the
129/Sv3 C57BL/6 F1 background carrying the Il22 construct were in-
jected into BALB/c blastocysts, which were then implanted in CD1
pseudopregnant foster mothers. Male chimeras were bred with
C57BL/6 to screen for germline-transmitted offspring. Mice bearing
the targeted IL-22 allele were screened by PCR. The derived heterozy-
gous mice were backcrossed onto the C57BL/6 genetic background656 Immunity 27, 647–659, October 2007 ª2007 Elsevier Inc.for 10 generations. Il22+/ mice were intercrossed to generate IL-22-
deficient and wild-type control mice. IL-17A-deficient mice on
a C57BL/6 stain (N9) were kindly provided by Y. Iwakura of the Univer-
sity of Tokyo, Japan (Nakae et al., 2002). IL-22 and IL-17 double-defi-
cient mice were generated by intercrossing the progeny of an IL-22-
deficient to IL-17-deficient cross. IL-6-deficient mice were obtained
from The Jackson Laboratories (Bar Harbor, ME) (Kopf et al., 1994).
C57BL/6 mice from the National Cancer Institute (Frederick, MD)
were used for cytokine induction experiments. Mice within experi-
ments were age and sex matched. Mice were cared for in accordance
with institutional animal care and use committee-approved protocols
at the Yale University School of Medicine animal facility.
Listeria monocytogenes Infection
To examine innate immunity, mice were intravenously injected via the
lateral tail vein with 5 3 104 CFU wild-type L. monocytogenes (strain
10403S). To quantitate bacterial burden, at day 3 after infection,
spleens and livers were homogenized in RPMI 1640, then lysed with
0.5% Triton X-100, serially diluted in PBS, then plated in triplicate
onto brain heart infusion agar plates. To examine the adaptive
response, micewere intravenously injectedwith 13 104 CFU recombi-
nant L. monocytogenes expressing ovalbumin (rLM-ova) as described
previously (Foulds et al., 2002). To assess T cell responses, L. mono-
cytogenes-infected mice were euthanized at day 7 after infection, as
well as uninfected control mice. Lymphocyte activation was measured
by direct ex vivo surface stain with fluorescently conjugated anti-CD4
(clone RM4-5), anti-CD44 (clone IM7), and anti-CD62L (clone MEL-14)
(all from BD PharMingen; San Jose, CA), followed by FACS analysis.
To quantitate antigen-specific CD4+ T cell responses, lymphocytes
from the spleens and livers were incubated with GolgiStop (BD
PharMingen) for 5 hr in the presence or absence of the peptide
LLO190-201. Cells were then surface stained for CD4 and intracellularly
stained for IFN-g (clone XMG1.2) with the Cytofix/Cytoperm kit (BD
PharMingen) according to the manufacturer’s protocol.
ConA Treatment
Mice were injected intravenously via the lateral tail vein with 10 mg/g of
conA (Sigma; St. Louis, MO) in PBS. Mice were euthanized at the indi-
cated time after injection.
Anti-Fas Treatment
Mice received 1 mg/g mouse of anti-Fas (clone Jo2) (BD PharMingen)
without preservatives by intraperitoneal injection (Ogasawara et al.,
1993).
Lymphocyte Preparation
Spleens and livers were aseptically removed from euthanized mice,
placed into cold Bruff’s media, and passed through a wire-mesh
screen. To prepare the spleen lymphocytes, RBCs were lysed with
ACK buffer. Splenocytes were resuspended in complete Bruff’s me-
dium containing 5% FCS, 2 mM L-glutamine, 100 U/ml penicillin,
and 100 mg/ml streptomycin. Aliquots were diluted in 0.1% trypan
blue in PBS to calculate the number of viable cells per spleen. Lympho-
cytes were isolated from the liver as previously described (Kuniyasu
et al., 2005), and liver homogenate was incubated with 100 U/ml colla-
genase (Sigma; St. Louis, MO) and 20 mg/ml DNase I (Sigma) for 40min
at 37C. To remove hepatocytes, homogenates were centrifuged at
300 rpm for 3 min, and then supernatants were centrifuged at 1500
rpm for 10 min. The cells were resuspended in 1 ml complete media
and 4 ml of 30% OptiPrep (Axis-Shield; Oslo, Norway) in a sodium
phosphate buffer, and 1ml of media was carefully layered on top. Cells
were centrifuged at 2700 rpm for 20 min. The top layer and interface
were harvested as the liver lymphocyte population.
ELISA
Sera were harvested from mice at the indicated times after injection.
TNF-a (eBioscience), IFN-g (BD PharMingen), and IL-17A (Southern
Immunity
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manufacturers’ protocols.
Flow Cytometry
Cells were stained with fluorescently conjugated Abs in 1% BSA in
PBS and subsequently fixed in 2% paraformaldehyde. The following
Abs were used: CD44 (clone IM7), CD62L (cloneMEL-14), CD69 (clone
H1.2F3), and CD4 (clone RM4-5) (all Ab from BD PharMingen). Cells
were analyzed with a FACSCalibur (BD Biosciences; San Jose, CA)
and data were analyzed by FlowJo v. 6.1 (TreeStar, Inc., Ashland, OR).
Histology
Organs were removed and fixed in 4% paraformaldehyde overnight at
4C, then embedded in paraffin, sectioned, and stained with H&E.
Slides were prepared at the Yale University Program for Critical Tech-
nologies in Molecular Medicine, Department of Pathology.
ALT and AST Assays
Serum ALT and AST were quantitated by colorimetric ALT and AST
enzyme assays (Biotron Diagnostics, Hemet, CA) with a modified
manufacturer’s protocol scaled to a 96-well plate format.
Real-Time RT-PCR
RNA from cells or organs was isolated with Trizol reagent (Invitrogen;
Carlsbad, CA) according to the manufacturer’s protocol. RNA was
subjected to reverse transcriptase with Superscript II (Invitrogen)
with oligo dT primer according to the manufacturer’s protocol. cDNA
was semiquantitated with commercially available primer and probe
sets (Applied Biosystems; Foster City, CA) and the DDCT method.
HPRT was included as an internal control for all samples.
Detection of Activated Stat3 and Akt
FL38B cells (ATCC CRL2390) were grown in F12K media supple-
mented with 10% FBS, 2 mM glutamine, 1.5 g/L sodium bicarbonate,
100 U/ml penicillin, and 100 mg/ml streptomycin. Cells were stimulated
for 20 min with the indicated concentration of recombinant murine IL-
22 (R&D Systems; Minneapolis, MN), IL-10 (BD PharMingen), or IL-17
(eBioscience; San Diego, CA). Cell lysates were separated under
reducing conditions on 4%–12% gradient gel with the NuPAGE elec-
trophoresis system (Invitrogen). Gels were transferred to Immobolin
P membrane (Millipore; Billerica, MA), blocked with 5% dry milk in
PBS with 0.01% Tween. Blots were then incubated overnight at 4C
with one of the following primary Ab: anti-phospho-Stat3 Tyr705 (poly-
clonal), anti-Stat3 (polyclonal), and anti-phospho-Akt Ser473 (clone
587F11) (all from Cell Signaling Technology; Danvers, MA) or anti-b-
actin (Santa Cruz Biotechnology; Santa Cruz, CA). Blots were washed,
incubated with appropriate secondary antibodies conjugated to
horseradish peroxidase, and then developed with chemiluminescent
substrate (Pierce, Rockford, IL) and film.
In Vitro CD4+ T Cell Differentiation
Naive sorted CD4+ T cells (CD4+ NK1.1 CD25 CD44low CD62Lhigh)
were cultured in complete Bruff’s media on plates coated with
10 mg/ml a-CD3 and 1 mg/ml a-CD28. The media was supplemented
with the following Abs and cytokines for the following differentiation
conditions: Th0, 10 mg/ml a-IFN-g (clone XMG) and 10 mg/ml a-IL-4
(clone 11B11); Th17, 1 ng/ml TGF-b (R&D Systems), 20 ng/ml IL-6
(BD PharMingen), 10 ng/ml IL-1b (BD PharMingen), 10 ng/ml TNF-
a (BD PharMingen), 10 mg/ml a-IL-4 and a-IFN-g. On day 5, cells
were extensively washed and then restimulated for 5 hr with 80 mM
PMA and 1 mM ionomycin. RNA was harvested and RT-PCR was per-
formed as described above.
Adoptive Transfer of Th17 Cells
Il22+/+ or Il22/ cells were cultured under Th17 conditions as de-
scribed above. On day 5, cells were extensively washed with PBS,
and then 5 3 106 cells were intraperitoneally injected into IL-22-defi-cient mice. 6 to 12 hr later, mice were injected intravenously with
10 mg/g conA.
Supplemental Data
Eight figures are available at http://www.immunity.com/cgi/content/
full/27/4/647/DC1/.
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